Incyte’s (INCY) performance in 2023 was tepid as pipeline setbacks and competition for lead drug Jakafi weighed on shares. Lead drug Jakafi (ruxolitinib) posted 8% growth in sales in the first three quarters of 2023. However, the FDA approval of GSK plc’s (GSK) momelotinib, under the brand name Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post- polycythemia vera and post-essential thrombocythaemia), in adults with anemia, ...